trial · primary record
FOLFIRINOX
Metastatic Pancreatic Cancer
| Phase | Phase 2 |
|---|---|
| Status | ACTIVE |
| Sponsor | Unknown |
| Enrolment | 37 |
| Primary completion | 2027-03-01 |
| Primary endpoint | To assess the toxicity profile of a regimen of alternating FOLFOX and FOLFIRI patients assessed as per NCI's CTCAE v5.0 criteria. |
| Registry ID | NCT05360732 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-10-29T14:32:39.851Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT05360732
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.